Physician profile
Anshuman Chawla
NPI 1841276417
$56,230.71
in general payments reported to CMS, 2019-2025
48 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,075 · 2020: $2,011 · 2021: $3,107 · 2022: $2,495 · 2023: $3,481 · 2024: $29K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $12K · Travel and Lodging: $4,508 · Consulting Fee: $875 · Education: $41.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,000.00 |
| Food and Beverage | $12,119.36 |
| Travel and Lodging | $4,507.63 |
| Consulting Fee | $875.00 |
| Education | $41.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34,392.05 | 2024-2025 | Voquezna |
| Abbvie INC. | $4,105.02 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $2,707.20 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $2,305.68 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,235.69 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Gilead Sciences, INC. | $1,196.44 | 2019-2025 | |
| Pfizer INC. | $896.32 | 2019-2025 | |
| Olympus Medical Systems Corporation | $875.00 | 2025 | Evis Exera III Duodenovideoscope |
| Ardelyx, INC. | $716.36 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $567.92 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $425.90 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $415.29 | 2019-2025 | Linzess |
| Genzyme Corporation | $395.19 | 2022-2025 | |
| Madrigal Pharmaceuticals | $350.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $347.67 | 2019-2025 | Sucraid, Sucraid |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $328.74 | 2021-2024 | Zeposia |
| Braintree Laboratories, INC. | $312.88 | 2019-2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $293.64 | 2019-2024 | Dificid |
| Allergan, INC. | $276.03 | 2019-2020 | |
| Ethicon US, LLC | $250.32 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $245.73 | 2019-2024 | Rebyota |
| Redhill Biopharma INC. | $236.27 | 2020-2023 | |
| Mauna Kea Technologies, INC. | $215.26 | 2019-2025 | |
| Lilly USA, LLC | $187.35 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $178.72 | 2025 | Iqirvo |
| Medtronic, INC. | $168.06 | 2023 | Endoflip |
| Evoke Pharma, INC. | $155.70 | 2021-2025 | Gimoti |
| Novo Nordisk INC | $144.43 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $133.56 | 2019-2023 | Ocaliva |
| Lucid Diagnostics INC. | $133.45 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $130.75 | 2023 | Zeposia |
| Shire North American Group INC | $129.23 | 2019 | |
| Celltrion USA INC. | $106.16 | 2024-2025 | Vegzelma, Zymfentra |
| Ucb, INC. | $99.04 | 2019 | |
| Alfasigma USA, INC. | $82.46 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $78.42 | 2024 | Dupixent |
| Boston Scientific Corporation | $67.65 | 2021 | |
| Alexion Pharmaceuticals, INC. | $58.77 | 2020-2023 | Ultomiris |
| Mirum Pharmaceuticals, INC. | $57.04 | 2025 | Livmarli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.14 | 2023 | Cyltezo |
| Alnylam Pharmaceuticals INC. | $43.29 | 2021-2022 | |
| Olympus America INC. | $24.94 | 2024 | Evis Exera III Colonovideoscope |
| Orphalan INC | $24.77 | 2025 | Cuvrior |
| Vivus LLC | $20.79 | 2023 | Pancreaze |
| Azurity Pharmaceuticals, INC. | $18.37 | 2025 | Sutab |
| Exact Sciences Corporation | $17.33 | 2023 | Cologuard Collection Kit |
| Dova Pharmaceuticals | $16.38 | 2019 | |
| Dynavax Technologies Corporation | $15.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshuman Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.